[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR9813149A - Complexo de carragenano, processo para preparação do mesmo, composição farmacêutica de liberação controlada, e, processos pra preparar composições farmecêuticas de liberação controlada na forma de tabletes e na forma de glânulos ou na forma de pelotas - Google Patents

Complexo de carragenano, processo para preparação do mesmo, composição farmacêutica de liberação controlada, e, processos pra preparar composições farmecêuticas de liberação controlada na forma de tabletes e na forma de glânulos ou na forma de pelotas

Info

Publication number
BR9813149A
BR9813149A BR9813149-4A BR9813149A BR9813149A BR 9813149 A BR9813149 A BR 9813149A BR 9813149 A BR9813149 A BR 9813149A BR 9813149 A BR9813149 A BR 9813149A
Authority
BR
Brazil
Prior art keywords
preparing
controlled
release pharmaceutical
granules
pharmaceutical composition
Prior art date
Application number
BR9813149-4A
Other languages
English (en)
Inventor
Carla Marcella Carmella
Maria Cristina Bonferoni
Original Assignee
Eurand Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Int filed Critical Eurand Int
Publication of BR9813149A publication Critical patent/BR9813149A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPLEXO DE CARRAGENANO, PROCESSO PARA PREPARAçãO DO MESMO, COMPOSIçãO FARMACêUTICA DE LIBERAçãO CONTROLADA, E, PROCESSOS PARA PREPARAR COMPOSIçõES FARMACêUTICAS DE LIBERAçãO CONTROLADA NA FORMA DE TABLETES E NA FORMA DE GRâNULOS OU NA FORMA DE PELOTAS" Complexo entre carragenano e drogas solúveis em água, caracterizado na forma de pó, tendo tamanho médio de partículas compreendido entre 10 e 100 Ám, e a droga básica aquosa está contida no complexo em quantidades de 1,5 a 5 mmoles/g de carragenano, um processo para preparar esse complexo e uma composição farmacêutica de liberação relativamente controlada que a contenha.
BR9813149-4A 1997-10-29 1998-10-29 Complexo de carragenano, processo para preparação do mesmo, composição farmacêutica de liberação controlada, e, processos pra preparar composições farmecêuticas de liberação controlada na forma de tabletes e na forma de glânulos ou na forma de pelotas BR9813149A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97PV000009A IT1297461B1 (it) 1997-10-29 1997-10-29 Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
PCT/EP1998/006864 WO1999021586A2 (en) 1997-10-29 1998-10-29 Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR9813149A true BR9813149A (pt) 2000-08-15

Family

ID=11397386

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813149-4A BR9813149A (pt) 1997-10-29 1998-10-29 Complexo de carragenano, processo para preparação do mesmo, composição farmacêutica de liberação controlada, e, processos pra preparar composições farmecêuticas de liberação controlada na forma de tabletes e na forma de glânulos ou na forma de pelotas

Country Status (13)

Country Link
US (1) US6355272B1 (pt)
EP (1) EP1030689B1 (pt)
JP (1) JP2001521010A (pt)
KR (1) KR20010031604A (pt)
AT (1) ATE238070T1 (pt)
AU (1) AU735337B2 (pt)
BR (1) BR9813149A (pt)
CA (1) CA2307863A1 (pt)
DE (1) DE69813872T2 (pt)
ES (1) ES2196632T3 (pt)
IT (1) IT1297461B1 (pt)
NZ (1) NZ504793A (pt)
WO (1) WO1999021586A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US20030229158A1 (en) * 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
KR101016619B1 (ko) * 2001-11-13 2011-02-23 아스텔라스세이야쿠 가부시키가이샤 용해성 약물 지속 방출 시스템
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
WO2003093322A2 (en) * 2002-04-30 2003-11-13 The Population Council, Inc. Carrageenan based antimicrobial compositions
US8367098B2 (en) 2002-04-30 2013-02-05 The Population Council, Inc. Unique combinations of antimicrobial compositions
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US20040091528A1 (en) * 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
DK1575565T3 (da) * 2003-08-08 2010-04-12 Biovail Lab Int Srl Tablet med modificeret frigivelse af bupropion-hydrochlorid
EP1768653A4 (en) 2004-06-25 2012-08-01 Univ Texas METHOD AND COMPOSITIONS FOR TREATING ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY AND HYPERPHENYL ALANINEMIA
CA2571554A1 (en) * 2004-06-28 2006-01-19 Alza Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
PT2262486E (pt) 2008-08-01 2013-03-27 Tovarna Zdravil D D Novo Mesto Krka Composição de quetiapina
JP2011068606A (ja) * 2009-09-25 2011-04-07 Kumamoto Univ 徐放性担体及び同徐放性担体を用いた薬剤並びに同薬剤を用いたドラッグデリバリーシステム
US9364549B2 (en) 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
WO2013169977A2 (en) * 2012-05-10 2013-11-14 Fmc Corporation Controlled release solid dose form

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5227M (pt) 1966-03-18 1967-08-14
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
DK171716B1 (da) 1982-03-12 1997-04-07 Pharmacia & Upjohn Ab Fremgangsmåde til fremstilling af et kompleks af carrageenan og emepronium, doxycyklin eller propranolol
JPS60174729A (ja) 1984-02-21 1985-09-09 Nippon Shinyaku Co Ltd 抗癌医薬組成物
US4613497A (en) 1984-02-29 1986-09-23 Health Products Development, Inc. Dry, water-foamable pharmaceutical compositions
JPS61130239A (ja) 1984-11-30 1986-06-18 Dai Ichi Seiyaku Co Ltd 複合体
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
SE9103110D0 (sv) 1991-10-24 1991-10-24 Kabi Pharmacia Ab New drug formulation

Also Published As

Publication number Publication date
IT1297461B1 (it) 1999-12-17
DE69813872T2 (de) 2004-02-26
KR20010031604A (ko) 2001-04-16
AU735337B2 (en) 2001-07-05
ES2196632T3 (es) 2003-12-16
NZ504793A (en) 2002-03-01
ATE238070T1 (de) 2003-05-15
EP1030689A1 (en) 2000-08-30
EP1030689B1 (en) 2003-04-23
AU1665199A (en) 1999-05-17
CA2307863A1 (en) 1999-05-06
US6355272B1 (en) 2002-03-12
WO1999021586A2 (en) 1999-05-06
ITPV970009A1 (it) 1999-04-29
JP2001521010A (ja) 2001-11-06
WO1999021586A3 (en) 1999-07-08
ITPV970009A0 (it) 1997-10-29
DE69813872D1 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
BR9813149A (pt) Complexo de carragenano, processo para preparação do mesmo, composição farmacêutica de liberação controlada, e, processos pra preparar composições farmecêuticas de liberação controlada na forma de tabletes e na forma de glânulos ou na forma de pelotas
NO20001670L (no) Fremgangsmate for fremstilling av en smaksmaskert farmasoytisk blanding og smaksmaskert farmasoytisk blanding fremstilt ifolge denne fremgangsmaten, samt smaksmaskerte tyggbare tabletter
NO940373D0 (no) Ikke-belagte tabletter og fremgangsmaate for fremstilling av disse
DK74187D0 (da) Praeparat til langsom frigivelse samt fremgangsmaade til fremstilling deraf
FI101384B1 (fi) Aktiiviaineen, joka on muu kuin lääkeaine, ja syklodekstriinin inkluusiokompleksi käytettäväksi kiinteässä kulutustuotekoostumuksessa
NZ502869A (en) Solid pharmaceutical dosage forms of glitazone in a particulate dispersion
HUP0103886A2 (hu) Azonnali hatóanyag-kibocsátású, peptidalapú trombininhibitort tartalmazó tabletta, eljárás előállítására és alkalmazása
IL92343A0 (en) Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
CA2025703A1 (en) Pulsatile once-a-day delivery systems for minocycline
EP0418596A3 (en) Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
BR9809651A (pt) Processo para a fabricação de pastilhas de flurbiprofen de forma losangular
PL321567A1 (en) Oral administration forms containing a beta-lactame antibiotic
ES2076358T3 (es) Granulados con elevado contenido de ibuprofeno.
NZ336592A (en) Formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml comprising finely divided budesonide and a carrier
ES2173595T3 (es) Encapsulado de ingredientes activos.
AU630740B2 (en) Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
FR2735136B1 (fr) Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
ES2040733T3 (es) Medicamentos que contienen clodronato y procedimiento para su preparacion.
ATE239456T1 (de) Pharmazeutische formulierung in form eines trockenen pulvers
FR2656772B1 (fr) Procede d'incorporation dans des pellets de principes actifs proteges contre la degradation dans la panse des ruminants.
HU9800512D0 (en) Salts of bismuthum and antibiotica of the moenomycin group, process for producing them, their use and pharmaceutical compositions containing them
HUP9800374A2 (en) Sulfonamide-substituted chromanes process for producing them, their use as medicines and pharmaceutical composition containing them
AU669902B2 (en) Pharmaceutical powder composition containing non-ionic cellulose ether derivative and a chitin-derived polymer
FR2705232B1 (fr) Procédé pour la préparation de particules préparées à sec, particules préparées à sec ainsi obtenues et compositions pharmaceutiques contenant de telles particules.
BR0016139A (pt) Produto sólido e processo para fabricar um produto sólido na forma de granulos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/69 (2017.01), A61K 47/61 (2017.0